Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Department of Health

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Department of Health

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Department of Health
07 March 2013
(37.33 Kb 10 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 01 March 2013